Citi lowered the firm’s price target on Lexicon (LXRX) to $1.20 from $4 and keeps a Buy rating on the shares after having updated its model for reported Q3 financial results. The firm assumes market penetration of Inpefa to be flat going forward, the analyst noted.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon announces completion of enrollment in Phase 2B PROGRESS study
- Lexicon price target lowered to $4 from $6 at H.C. Wainwright
- Lexicon to eliminate commercial organization, focus on clinical development
- Lexicon Pharmaceuticals Appoints Ivan Cheung to Board
- Lexicon announces data from four stories of sotagliflozin to be delivered